Publication

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL
J Clin Oncol. 2014 32 (12): 1202-9

PMID: 24663045 · PMCID: PMC3986383 · DOI:10.1200/JCO.2013.54.0518

MeSH Terms (26)

Adult Aged Aminopyridines Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms Cell Line, Tumor Class I Phosphatidylinositol 3-Kinases Dose-Response Relationship, Drug Drug Administration Schedule Female Fluorodeoxyglucose F18 Humans Letrozole Middle Aged Morpholines Multimodal Imaging Nitriles Phosphoinositide-3 Kinase Inhibitors Positron-Emission Tomography Protein Kinase Inhibitors Radiopharmaceuticals Receptor, ErbB-2 Receptors, Estrogen Tomography, X-Ray Computed Triazoles

Connections (3)

This publication is referenced by other Labnodes entities:

Links